APA (7th ed.) Citation

J, W., J, C., L, G., M, Y., J, S., Y, Z., . . . L, W. (2026). Chronic portal hypertension following inotuzumab ozogamicin in a low-risk patient: A case of overriding baseline risk and long-term management. Annals of hematology, 105(1), 4. https://doi.org/10.1007/s00277-026-06809-4

Chicago Style (17th ed.) Citation

J, Wu, et al. "Chronic Portal Hypertension Following Inotuzumab Ozogamicin in a Low-risk Patient: A Case of Overriding Baseline Risk and Long-term Management." Annals of Hematology 105, no. 1 (2026): 4. https://doi.org/10.1007/s00277-026-06809-4.

MLA (9th ed.) Citation

J, Wu, et al. "Chronic Portal Hypertension Following Inotuzumab Ozogamicin in a Low-risk Patient: A Case of Overriding Baseline Risk and Long-term Management." Annals of Hematology, vol. 105, no. 1, 2026, p. 4, https://doi.org/10.1007/s00277-026-06809-4.